As we continue progressing our pipeline of high-precision cell therapies, we have several openings across commercial, manufacturing, operations and other functions from entry-level to leadership. Interested in a role? Check out our Careers page: orcabio.com/culture-careers/ #CellTherapy #Hematology #Oncology

ICYMI: @ASTCT_Journal recently published data highlighting long-term overall survival outcomes associated with our FDA-approved high-precision cell therapy for allogeneic transplant in people with hematologic malignancies. The three-year findings provide important insight into the potential long-term impact of innovative approaches to improving transplant outcomes. Learn more: orcabio.com/orca-bio-announc… #CellTherapy #Hematology #Oncology

We’re thrilled to be attending @alliancerm's Cell & Gene Meeting on the Mesa October 5-7, where our Co-founder and CEO Nate Fernhoff will speak on our pipeline of high-precision cell therapies and commercialization of our first FDA approved therapy. Learn more about the discussion: meetingonthemesa.com/agenda/ #Hematology #Oncology #CellTherapy

Today is #WorldALLDay, an opportunity to raise awareness of acute lymphoblastic leukemia (ALL) and the ongoing need for innovation on behalf of patients and families. According to @AmericanCancer an estimated over 6,000 new cases of ALL will be diagnosed in the U.S. in 2026, highlighting the continued need for patients to have new and effective treatment options. At Orca Bio, we’re committed to advancing high-precision cell therapies for patients with ALL and other blood cancers. Learn more: orcabio.com/our-pipeline/ #WorldALLDay #CellTherapy #Hematology #Oncology

At Orca Bio, manufacturing is more than infrastructure. It’s a critical part of our mission to expand access to high-precision cell therapies for patients who need them most. Our 100,000-square-foot manufacturing facility was built to support the reliable, consistent delivery of these therapies. As we continue to grow, our manufacturing capabilities remain essential to bringing the promise of cell therapy to more patients. #CellTherapy #Manufacturing #Biotech #Oncology #Hematology #OrcaBio

Today is #WorldLeukemiaDay, a time to raise awareness of leukemia and recognize the patients, families, caregivers and communities impacted by this disease. According to @BloodCancerUtd the fifth leading cause of cancer deaths among adults ages 20-39 is leukemia, underscoring the continued need for new treatment approaches and improved outcomes. At Orca Bio, we remain committed to advancing high-precision cell therapies with the potential to improve outcomes for patients living with leukemia and other blood cancers. Learn more: orcabio.com/our-pipeline/ #WLD26 #CellTherapy #Hematology #Oncology

This #BloodCancerAwarenessMonth, we’re reminded that behind every statistic is a patient, a family and a story. We’re spotlighting Kelly Terell, Orca Account Manager at Orca Bio, whose connection to this mission is deeply personal. After seeing a family member pass away from lymphoma when she was young, Kelly was led to a career in nursing and later cell and gene therapy. That experience continues to shape her work today as she helps inform treatment centers of Orca Bio’s recent FDA approved high-precision cell therapy. Thank you, Kelly, for your commitment to advancing high-precision cell therapies for patients with blood cancers. Learn more: orcabio.com/our-pipeline/ #EmployeeSpotlight #Oncology #Hematology #CellTherapy

We’re looking forward to attending the fourteenth annual meeting of the @SocietyofHemOnc #SOHO where we will present clinical data across our investigational high-precision cell therapy programs. Learn more about our #SOHO2026 presentations: orcabio.com/orca-bio-to-pres… #Hematology #Oncology #CellTherapy

As we close out #WorldCancerSupportMonth, we’re honoring the courage of patients, survivors and caregivers throughout every stage of the cancer journey. We're honored to share the story of Larry, an Orca Bio clinical trial participant living with #MDS. After receiving a life-changing diagnosis, Larry found strength in the community around him. Through real-time support from family and regular email updates to those in his network, he’s kept friends and family connected to his journey, transforming support into a source of resilience and hope. At Orca, we're inspired by patients like Larry and the networks of care that help carry them forward. Their courage fuels our commitment to advancing high-precision cell therapies for patients with blood cancers. ​​​ #WorldCancerSupportMonth #PatientsFirst #CellTherapy #Hematology #Oncology

As we continue to ramp up our manufacturing efforts, we have numerous openings across manufacturing, operations, quality and other functions ranging from entry level to mid-career and leadership. Think you might be a good fit? Check out our Careers page: orcabio.com/culture-careers/ #CellTherapy #Manufacturing #Hematology #Oncology

This month’s #EmployeeSpotlight is Anthony Prieto, Manufacturing Science and Technology (MSAT) Manager. ​​In his role on #TeamOrcaBio​​​​​​​ ​Anthony helps our MSAT processes run smoothly and reliably, so ​that ​we can deliver cell therapies to patients. Learn more about what ​​motivates​​​​ Anthony every day. #CellTherapy #Hematology #Oncology #BiotechCareers

Join our Chief Development Officer, Scott McClellan, MD, Ph.D., on August 20th for a webcast with PBSS and BioScience Forum on advances in cancer therapeutics. Scott will share insights on managing the clinical complexities of our high-precision cell therapies. Register for the free ​event ​here: pbss.org/eventDetails/1090 #CellTherapy #Hematology #Oncology

As we move into the second half of 2026, we’re energized by all #TeamOrcaBio has accomplished this year, including our first U.S. FDA approval. We’re looking forward to building on this momentum as we continue to advance our high-precision cell therapies for patients. #CellTherapy #CancerResearch #BloodCancer

Advancing care for patients requires strong advocacy across the healthcare community. We are grateful to organizations like the @MDSFoundation that provide critical education, advocacy and support for patients and families affected by myelodysplastic syndromes. #PatientsFirst #CellTherapy

Chronic graft​ ​versus ​host disease (#GVHD) remains a potentially serious complication after allogeneic stem cell transplant. Learn more about results from the pivotal Phase 3 Precision-T trial which supported the U.S. FDA approval ​of our ​precision-engineered​​​​​​ cell therapy for allogeneic transplant in people with hematological malignancies: bit.ly/4vGQOU0 #CellTherapy #BloodCancer #PrecisionToLife

Following last week’s FDA approval, we are officially stepping into an exciting new chapter. We want to express our gratitude to the patients, providers, advocates​ and everyone at #TeamOrcaBio who made the approval of our precision-engineered cell therapy for allogeneic transplant in people with hematological malignancies possible.   ​​​   Read more: bit.ly/4vGQOU0 #CellTherapy

We are proud to announce the U.S. FDA approval of our new ​​precision-engineered cell therapy for allogeneic transplant in people with hematologic malignancies. This marks a significant milestone for Orca Bio, ​​and most importantly, for the patients we serve.  ​​​​​​   Learn more: bit.ly/4vGQOU0 #CellTherapy #BloodCancer

Innovation in cell therapy is evolving the way patients living with #bloodcancer are treated. We’re proud to be at the forefront of advancing a pipeline of investigational therapies designed to deliver more precise, differentiated approaches for patients. Learn more about our therapies: bit.ly/4b4E3tT #CellTherapy

Orca Bio announces new East Coast manufacturing capacity and the strategic expansion of its Sacramento-based manufacturing team ahead of potential launch. Read more in our press release: bit.ly/4uGIGl5

As we mark Pride Month, we’re reflecting on what it truly means to foster an environment built on celebrating one another for exactly who we are. At Orca Bio, it's about the daily efforts that ensure every individual feels secure enough to be themselves. Our Chief Financial Officer, Josh Murray, shares his perspective on why this matters to our team. For him, inclusion is a commitment to actively supporting our people, laying the essential groundwork that empowers our people to bring their full potential to the table. We are proud to stand with our LGBTQ+ community this month and every month, continuing the daily work of building a culture where everyone belongs. #Pride2026 #CultureOfBelonging